Display options
Cite
Murray-Thomas T, Jones ME, Patel D, et al. Risk of mortality (including sudden cardiac death) and major cardiovascular events in atypical and typical antipsychotic users: a study with the general practice research database. Cardiovasc Psychiatry Neurol. 2013;2013:247486doi: 10.1155/2013/247486.
Murray-Thomas, T., Jones, M. E., Patel, D., Brunner, E., Shatapathy, C. C., Motsko, S., & Van Staa, T. P. (2013). Risk of mortality (including sudden cardiac death) and major cardiovascular events in atypical and typical antipsychotic users: a study with the general practice research database. Cardiovascular psychiatry and neurology, 2013247486. https://doi.org/10.1155/2013/247486
Murray-Thomas, Tarita, et al. "Risk of mortality (including sudden cardiac death) and major cardiovascular events in atypical and typical antipsychotic users: a study with the general practice research database." Cardiovascular psychiatry and neurology vol. 2013 (2013): 247486. doi: https://doi.org/10.1155/2013/247486
Murray-Thomas T, Jones ME, Patel D, Brunner E, Shatapathy CC, Motsko S, Van Staa TP. Risk of mortality (including sudden cardiac death) and major cardiovascular events in atypical and typical antipsychotic users: a study with the general practice research database. Cardiovasc Psychiatry Neurol. 2013;2013:247486. doi: 10.1155/2013/247486. Epub 2013 Dec 26. PMID: 24455199; PMCID: PMC3888674.
Copy Download .nbib Format: NLM
Share it on

Cardiovasc Psychiatry Neurol. 2013;2013:247486. doi: 10.1155/2013/247486. Epub 2013 Dec 26.

Risk of mortality (including sudden cardiac death) and major cardiovascular events in atypical and typical antipsychotic users: a study with the general practice research database.

Cardiovascular psychiatry and neurology

Tarita Murray-Thomas, Meghan E Jones, Deven Patel, Elizabeth Brunner, Chetan C Shatapathy, Stephen Motsko, Tjeerd P Van Staa

Affiliations

  1. Clinical Practice Research Datalink, Medicines and Healthcare Products Regulatory Agency, London SWIW 9SZ, UK.
  2. Eli Lilly and Company, Indianapolis, IN, USA.
  3. Clinical Practice Research Datalink, Medicines and Healthcare Products Regulatory Agency, London SWIW 9SZ, UK ; London School of Hygiene & Tropical Medicine, London, UK ; Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.

PMID: 24455199 PMCID: PMC3888674 DOI: 10.1155/2013/247486

Abstract

Objective. Antipsychotics have been associated with increased cardiac events including mortality. This study assessed cardiac events including mortality among antipsychotic users relative to nonusers. Methods. The General Practice Research Database (GPRD) was used to identify antipsychotic users, matched general population controls, and psychiatric diseased nonusers. Outcomes included cardiac mortality, sudden cardiac death (SCD), all-cause mortality (excluding suicide), coronary heart disease (CHD), and ventricular arrhythmias (VA). Sensitivity analyses were conducted for age, dose, duration, antipsychotic type, and psychiatric disease. Results. 183,392 antipsychotic users (115,491 typical and 67,901 atypical), 544,726 general population controls, and 193,920 psychiatric nonusers were identified. Nonusers with schizophrenia, dementia, or bipolar disorder had increased risks of all-cause mortality compared to general population controls, while nonusers with major depression had comparable risks. Relative to psychiatric nonusers, the adjusted relative ratios (aRR) of all-cause mortality in antipsychotic users was 1.75 (95% CI: 1.64-1.87); cardiac mortality 1.72 (95% CI: 1.42-2.07); SCD primary definition 5.76 (95% CI: 2.90-11.45); SCD secondary definition 2.15 (95% CI: 1.64-2.81); CHD 1.16 (95% CI: 0.94-1.44); and VA 1.16 (95% CI: 1.02-1.31). aRRs of the various outcomes were lower for atypical versus typical antipsychotics (all-cause mortality 0.83 (95% CI: 0.80-0.85); cardiac mortality 0.89 (95% CI: 0.82-0.97); and SCD secondary definition 0.76 (95% CI: 0.55-1.04). Conclusions. Antipsychotic users had an increased risk of cardiac mortality, all-cause mortality, and SCD compared to a psychiatric nonuser cohort.

References

  1. Ther Adv Drug Saf. 2012 Apr;3(2):89-99 - PubMed
  2. Am J Psychiatry. 2010 Jun;167(6):686-93 - PubMed
  3. Encephale. 2000 Nov-Dec;26(6):32-41 - PubMed
  4. JAMA. 2005 Oct 19;294(15):1934-43 - PubMed
  5. Arch Gen Psychiatry. 2001 Dec;58(12):1161-7 - PubMed
  6. Am J Epidemiol. 1984 Dec;120(6):888-99 - PubMed
  7. Pharmacoepidemiol Drug Saf. 2007 May;16(5):538-44 - PubMed
  8. J Nerv Ment Dis. 1999 Aug;187(8):496-502 - PubMed
  9. Circulation. 1995 Mar 15;91(6):1749-56 - PubMed
  10. Clin Ther. 1995 Nov-Dec;17(6):1062-77 - PubMed
  11. J Am Coll Cardiol. 1985 Jun;5(6 Suppl):141B-149B - PubMed
  12. Am J Psychiatry. 2007 Mar;164(3):415-27 - PubMed
  13. J Am Coll Cardiol. 1986 Jul;8(1 Suppl A):104A-109A - PubMed
  14. Br J Psychiatry. 2008 Jan;192(1):12-8 - PubMed
  15. J Affect Disord. 1998 Sep;50(2-3):277-82 - PubMed
  16. Am J Epidemiol. 2007 Mar 15;165(6):710-8 - PubMed
  17. J Nerv Ment Dis. 2004 Jan;192(1):19-27 - PubMed
  18. Arch Gen Psychiatry. 2007 Feb;64(2):242-9 - PubMed
  19. Psychosomatics. 2004 Sep-Oct;45(5):371-7 - PubMed
  20. N Engl J Med. 2005 Dec 1;353(22):2335-41 - PubMed
  21. Br J Psychiatry. 1996 Nov;169(5):647-54 - PubMed
  22. Br J Psychiatry. 1996 Jun;168(6):772-9 - PubMed
  23. Medicine (Baltimore). 1967 Jul;46(4):341-61 - PubMed
  24. Diabetes Care. 2004 Feb;27(2):596-601 - PubMed
  25. Hosp Community Psychiatry. 1991 Dec;42(12):1248-51 - PubMed
  26. BMJ. 2012 Feb 23;344:e977 - PubMed
  27. Br J Psychiatry. 2012 May;200(5):393-8 - PubMed
  28. Circulation. 2002 Jun 4;105(22):2595-9 - PubMed
  29. Drug Saf. 1997 Oct;17(4):265-75 - PubMed
  30. Br J Clin Pharmacol. 1999 Mar;47(3):307-13 - PubMed
  31. J Clin Psychiatry. 2004 May;65(5):715-20 - PubMed
  32. Br J Psychiatry. 2000 Jan;176:76-82 - PubMed
  33. J Am Geriatr Soc. 2008 Sep;56(9):1644-50 - PubMed
  34. Pharmacoepidemiol Drug Saf. 2010 Jun;19(6):555-62 - PubMed
  35. N Engl J Med. 2004 Sep 9;351(11):1089-96 - PubMed
  36. J Clin Epidemiol. 1996 Aug;49(8):865-8 - PubMed
  37. Br J Psychiatry. 1997 Feb;170:186-90 - PubMed
  38. CNS Drugs. 2007;21(11):911-36 - PubMed
  39. CMAJ. 2007 Feb 27;176(5):627-32 - PubMed
  40. N Engl J Med. 2009 Jan 15;360(3):225-35 - PubMed
  41. Ann Intern Med. 2007 Jun 5;146(11):775-86 - PubMed
  42. J Am Coll Cardiol. 2009 Mar 17;53(11):950-8 - PubMed
  43. Br J Clin Pharmacol. 2010 Jan;69(1):4-14 - PubMed
  44. J Gerontol. 1993 Nov;48(6):S289-300 - PubMed
  45. Circulation. 1996 Jun 1;93(11):2033-6 - PubMed
  46. Pharmacoepidemiol Drug Saf. 2008 Dec;17(12):1131-6 - PubMed

Publication Types

Grant support